Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study.
Yang DuXiao-Yan LiuXiao-Yan SiXiao-Tong ZhangJing-Ya ZhouYi WangMin-Jiang ChenLi ZhangPublished in: Translational lung cancer research (2024)
Anlotinib shows the potential to extend PFS and manageable adverse events (AEs) compared to topotecan in the second-line setting for relapsed SCLC.